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Abstract 
Background: Proteinuria has been recognized as a marker of systemic inflammation and endothelial dysfunction 
associated with insulin resistance and β-cell impairment, which can contribute to the development of type 2 diabetes 
mellitus (T2DM). However, it is unknown whether the dipstick proteinuria test has a predictive value for new-onset 
T2DM.
Methods: This retrospective cohort study analyzed 239,287 non-diabetic participants who participated in the Korean 
nationwide health screening program in 2009–2010. Proteinuria was determined by the urine dipstick test at the 
baseline health screening. We performed multivariate Cox proportional regression analyses for the development of 
new-onset T2DM. Follow-up was performed until December 2015.
Results: During the mean follow-up period of 5.73 years, 22,215 participants were diagnosed with new-onset T2DM. 
The presence of proteinuria was significantly associated with an increased risk of T2DM (adjusted hazard ratio: 1.19, 
95% confidence interval: 1.10, 1.29). There was a positive dose–response relationship between the degree of dipstick 
proteinuria and T2DM risk. This significant association between proteinuria and T2DM risk was consistent regardless of 
the fasting glucose level at baseline.
Conclusions: Dipstick proteinuria is a significant risk factor for new-onset T2DM. Therefore, proteinuria might be a 
useful biomarker to identify those at a high risk for developing T2DM.
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Background
Type 2 diabetes mellitus (T2DM), a chronic metabolic 
disorder characterized by hyperglycemia with abnormal 
glucose regulation, is a major public health concern due 
to its high prevalence and increasing disease burden [1, 
2]. Since T2DM is considered to be largely preventable, 
developing strategies to prevent T2DM and its complica-
tions is an important health topic [3]. For the prevention 
of T2DM, identifying risk factors and screening at-risk 
populations are crucial steps [4].
Proteinuria is the presence of excess proteins in the 
urine and has been primarily recognized as a marker 
of kidney damage and a predictor of future decline in 
renal function [5]. Increased inflammatory response and 
endothelial dysfunction are representative clinical fea-
tures of proteinuria [6]. The systemic inflammation and 
endothelial dysfunction are common features of diabetes 
and are closely related to insulin resistance [7, 8]. Regard-
ing inflammatory markers and endothelial dysfunction 
frequently precede the development of T2DM and they 
are predictive biomarkers for T2DM, we hypothesized 
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new-onset T2DM [9–12]. The urine dipstick test for 
proteinuria is widely used in clinical practice and pub-
lic health screenings because of its low cost, ease of use, 
rapid results, and acceptable accuracy [13, 14]. There 
were some prior studies for the association between pro-
teinuria and the development of T2DM [15–17]. How-
ever, role of dipstick proteinuria on risk for T2DM is not 
well-known, and few studies have investigated in Korea. 
In the current study, we aimed to investigate whether 
non-diabetic participants with dipstick proteinuria are 
at an increased risk of new-onset T2DM using a Korean 
nationwide population-based cohort database.
Methods
Data source and study design
Current study had a retrospective cohort design and used 
data from the National Health Insurance Service-Health 
Screening Cohort (NHIS-HEALS) in Korea. Information 
on the dataset has been reported in detail elsewhere [18]. 
Briefly, the NHIS-HEALS comprises approximately 51 
million Korean adults through a random selection of 10% 
of all health screening participants aged 40–79 years. The 
NHIS-HEALS contains the participants’ demograph-
ics, health claims data, death statistics, and serial health 
screening program results. The health screenings were 
conducted every 2  years between 2002 and 2015 and 
included a physical examination, lifestyle survey, labora-
tory tests including fasting serum glucose levels, and dip-
stick urinalysis for proteinuria. From the health claims 
data, the participants’ diagnoses, made at each hospital, 
were recorded according to the International Statistical 
Classification of Diseases and Related Health Problems 
10th Revision. Data from the NHIS-HEALS are fully 
anonymized. The study participants were non-diabet-
ics who underwent a health examination in 2009–2010 
(baseline health examination). We excluded participants 
who had a history of diabetes and those who had no dip-
stick proteinuria data or covariate data from the baseline 
health examination. A flow chart of the inclusion pro-
cess is shown in Fig. 1. From the date of baseline health 
examination (index date), the participants were followed 
up until the development of new-onset T2DM (primary 
outcome), death, loss of eligibility for NHIS due to emi-
gration, or December 2015, whichever occurred earli-
est. This study was approved by the Institutional Review 
Board of Yongin Severance Hospital (9–2020-0106), and 
the need for informed consent was waived due to its ret-
rospective nature and analysis with anonymized data.
Proteinuria and study outcome assessment
As part of the health screening program, a dipstick uri-
nalysis was performed using urine samples obtained 
in the morning after overnight fasting. Proteinuria was 
determined through an interpretation of the dipstick 
urinalysis results based on a color scale that quantifies 
proteinuria as ‘negative’, ‘trace (±)’, ‘1 + ’, ‘2 + ’, ‘3 + ’, or 
‘4 + ’. For this study, we classified the dipstick proteinuria 
results into three groups: ‘no proteinuria (-)’, ‘trace (±)’, 
and ‘overt proteinuria (≥ 1 +)’. The incidence of primary 
outcome (new-onset T2DM) was defined as the presence 
of one of the following two conditions: a health claim 
code of E11-E14 with the prescription of any anti-dia-
betic drug (insulin, sulfonylurea, metformin, meglitinide, 
thiazolidinedione, dipeptidyl peptidase-4 inhibitor, or 
α-glucosidase inhibitor) during follow-up or a fasting 
serum glucose level ≥ 126 mg/dL obtained from the serial 
health screening program data [19, 20].
Covariates
Demographic and lifestyle characteristics including sex, 
age, current smoking, alcohol consumption, physical 
activity, and family history of diabetes were collected 
from self-reported questionnaires at the health screening. 
Alcohol consumption was categorized into < 1 time, 1–2 
times, 3–4 times, and ≥ 5 times based on weekly intake 
frequencies on average. Physical activity was divided 
into < 1 day, 1–4 days, and ≥ 5 days per week, according 
to the number of days of exercise on average. The pres-
ence of hypertension was determined if participants had 
a systolic/diastolic blood pressure ≥ 140/90  mmHg or 
answered “yes” in the corresponding health screening 
questionnaire concerning a diagnosis of hypertension. 
Body mass index was calculated by dividing the body 
weight (kg) by the height squared  (m2), then categorized 
into underweight (< 18.5  kg/m2), normal (18.5–23  kg/
m2), overweight (23–25  kg/m2), or obese (≥ 25  kg/m2) 
using the body mass index criteria of the World Health 
Organization for Asians [21]. Estimated glomerular fil-
tration rate was calculated using the Modification of 
Diet in Renal Disease formula: Estimated glomeru-
lar filtration rate (mL/min/1.73  m2) = 186.3 × (serum 
 creatinine—1.154) ×  (age—0.203) × (0.742) for women [22]. 
Fasting glucose levels at baseline were divided into 
two groups: normal fasting glucose (< 100  mg/dL) and 
impaired fasting glucose (≥ 100 mg/dL and < 126 mg/dL), 
in accordance with the American Diabetes Association 
criteria [23].
Statistical analyses
Categorical variables are presented as numbers (%), and 
continuous variables are presented as mean (standard 
deviation). Differences between groups were compared 
using the Mantel–Haenszel test for linear trend for cat-
egorical variables and the Jonckheere’s trend test for con-
tinuous variables. We illustrated Kaplan–Meier curves 
for event-free survival for T2DM development according 
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to dipstick proteinuria, which were compared using a 
log-rank test. Cox proportional hazard regression analy-
sis was performed to estimate the hazard ratio (HR) and 
95% confidence interval (CI) for the risk of T2DM. In the 
multivariate Cox models, adjustments were made for sex, 
age, current smoking, physical activity, alcohol consump-
tion, family history of diabetes, body mass index, sys-
tolic blood pressure, fasting glucose level, and estimated 
glomerular filtration rate at baseline. The SAS version 
9.4 (SAS Inc., Cary, NC, USA) and R software version 
3.3.3 (The R Foundation for Statistical Computing, 
Vienna, Austria; http:// www.R- proje ct. org/) were used to 
manipulate the data and perform all statistical analyses. 
The statistically significant level for all tests was defined 
as two-sided P < 0.05.
Results
Baseline characteristics
In accordance with the inclusion and exclusion criteria 
(Fig. 1), 239,287 participants were included in the study. 
The baseline characteristics of the participants according 
to degree of proteinuria are shown in Table 1. Among the 
239,287 participants, 95.9% (n = 229,426) did not have 
proteinuria, 2.1% (n = 5,054) had trace proteinuria (±), 
Prior history of diabetes




377,641 health screening participants  
in 2009 of NHIS-HEALS
Missing data on dipstick  
proteinuria were excluded  
(n = 752)




239,287 participants were 
available  for the analysis
Fig. 1 Flowchart of Included participants. NHIS-HEALS, the National Health Insurance Service-Health Screening Cohort
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and 2.0% (n = 4,807) had overt proteinuria (≥ 1 +). The 
degree of proteinuria was positively associated with sex, 
current smoking, alcohol consumption, and obesity. A 
significantly increasing and decreasing trend according 
to the degree of proteinuria was observed for the level 
of systolic blood pressure, fasting glucose and estimated 
glomerular filtration rate at baseline, respectively.
Risk of T2DM according to proteinuria
During the mean follow-up period of 5.73 (standard 
deviation, 1.18) years, 22,215 participants had new-
onset T2DM. A Kaplan–Meier curve for the cumulative 
risk of new-onset T2DM showed an increased risk for 
T2DM according to the presence and degree of proteinu-
ria (Fig. 2). In the univariate Cox regression models, the 
risk of new-onset T2DM was significantly higher in the 
overt proteinuria group than in the group without pro-
teinuria (crude HR: 1.50; 95% CI: 1.38, 1.62). This positive 
association with proteinuria was maintained in the fully 
adjusted model (adjusted HR: 1.19; 95% CI: 1.10, 1.29) 
(Table 2).
Risk of T2DM according to proteinuria and fasting glucose 
level
To investigate whether the association between pro-
teinuria and new-onset T2DM risk differed accord-
ing to risk factors, subgroup analyses were performed 
(Additional file  1: Fig. S1). In sex, age, and other sub-
groups, significant interaction effects with proteinuria 
for T2DM risk were nor found (P > 0.05). To further 
evaluate whether there were interaction effects between 
proteinuria and baseline fasting glucose levels, we clas-
sified participants according to their baseline fasting 
glucose levels into the normal fasting glucose group 
(< 100  mg/dL) and the impaired fasting glucose group 
(≥ 100 mg/dL and < 126 mg/dL). In both groups, overt 
proteinuria was significantly associated with increased 
risk for new-onset T2DM compared with no proteinu-
ria (Additional file 2: Table S1).
Table 1 Baseline characteristics of participants according to degree of proteinuria
Data are represented as the number of participants (%) or mean ± standard deviation. †P for trends are derived from the Mantel–Haenszel test for linear trend and the 
Jonckheere’s trend test
Variable Total Degree of proteinuria P for  trend†
No proteinuria Trace proteinuria (±) Overt proteinuria (≥ 1 +)
N 239,287 229,426 5054 4807
Sex, male 128,780 (53.82) 123,210 (53.70) 2881 (57.00) 2689 (55.94)  < 0.001
Age, years 57.12 ± 8.33 57.09 ± 8.31 57.10 ± 8.68 58.50 ± 9.05  < 0.001
Current smoking 42,824 (17.90) 40,863 (17.81) 1014 (20.06) 947 (19.70)  < 0.001
Alcohol consumption, frequency per week  < 0.001
  < 1 time 141,913 (59.13) 136,296 (59.41) 2811 (55.62) 2806 (58.37)
 1–2 times 64,760 (27.06) 62,011 (27.03) 1511 (29.90) 1238 (25.75)
 3–4 times 21,364 (8.93) 20,418 (8.90) 491 (9.72) 455 (9.47)
  ≥ 5 times 11,250 (4.70) 10,701 (4.66) 241 (4.77) 308 (6.41)
Exercise, days per week 0.398
  < 1 day 59,871 (25.02) 57,433 (25.03) 1149 (22.73) 1289 (26.82)
 1–4 days 108,348 (45.28) 103,860 (45.27) 2353 (46.56) 2135 (44.41)
  ≥ 5 days 71,068 (29.70) 68,133 (29.70) 1552 (30.71) 1383 (28.77)
Body mass index  < 0.001
 Underweight (< 18.5 kg/m2) 5548 (2.32) 5280 (2.30) 129 (2.55) 139 (2.89)
 Normal range (18.5–23 kg/m2) 90,072 (37.64) 86,733 (37.80) 1782 (35.26) 1577 (32.39)
 Overweight (23–25 kg/m2) 67,809 (28.34) 65,153 (28.40) 1435 (28.39) 1221 (25.40)
 Obese (≥ 25 kg/m2) 75,858 (31.70) 72,260 (31.50) 1708 (33.80) 1890 (39.32)
Hypertension 128,316 (53.62) 122,251 (53.29) 2906 (57.50) 3159 (65.72)  < 0.001
Systolic blood pressure, mmHg 124.27 ± 15.12 124.17 ± 15.04 125.25 ± 15.89 128.34 ± 17.41  < 0.001
Family history of diabetes, yes 17,836 (7.45) 17,060 (7.44) 434 (8.59) 342 (7.11) 0.539
Laboratory findings
 Fasting glucose, mg/dL 94.13 ± 11.20 94.07 ± 11.17 95.05 ± 11.48 95.91 ± 11.91  < 0.001
 Estimated glomerular filtration rate, mL/
min/1.73  m2
83.66 ± 34.40 83.87 ± 34.43 79.60 ± 36.53 77.92 ± 29.18  < 0.001
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Risk of T2DM according to the change in proteinuria status
We further analyzed the risk for new-onset T2DM 
according to the change in proteinuria status. 
For this analysis, we collected data on partici-
pants who also underwent a health examination 
between 2002 and 2003 that included a dipstick pro-
teinuria test (n = 238,679). The participants were 
divided into four groups according to the change 
in proteinuria: Negative/Trace → Negative/Trace 
(− → −; Group 1), Negative/Trace →  ≥ 1 + (− →  + ; 
Group 2), ≥ 1 +  → Negative/Trace (+ → −; Group 
3), ≥ 1 +  →  ≥ 1 + (+ →  + ; Group 4). In the analy-
ses, group 1 (− → −) had lower risk for new-onset 
T2DM compared with the other three groups (Table 3). 
Change in lifestyle characteristics (smoking status, 
physical activity, alcohol consumption) of study par-
ticipants according to change in proteinuria status are 
shown in Additional file 3: Table S2.
Discussion
This cohort study investigated the association between 
dipstick proteinuria and the risk of new-onset T2DM 
using the nationwide population-based health screen-
ing database in Korea. Participants with proteinuria had 
a higher risk of developing T2DM independent of other 
risk factors, including fasting glucose level. There was a 
dose-dependent increase in the risk of T2DM according 
to the degree of dipstick proteinuria. The urine dipstick 
test is already a widely used screening tool for proteinuria 
and other urinary issues [24]. Our study implies that the 
dipstick proteinuria test may also be useful for identify-
ing patients at high risk of developing T2DM.
There are several potential mechanisms that may 
help explain the relationship between proteinuria and 
increased T2DM risk. The first is that proteinuria is a 
sensitive marker of inflammation, and sustained pro-
teinuria is considered a cause of further inflammation 
and oxidative stress [25, 26]. Numerous studies have 
documented a strong positive relationship between pro-
teinuria and inflammatory biomarkers such as C-reactive 
protein, TNF-α, interleukin-6, and monocyte chemotac-
tic protein-1 [27, 28]. In a large cohort of chronic kidney 
disease patients, the inflammation score was positively 
associated with proteinuria, regardless of estimated glo-
merular filtration rate [29]. Recent evidence has sug-
gested that proteinuria itself and underlying medical 
conditions can elicit pro-inflammatory effects and the 
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Fig. 2 Kaplan Meier curves for the Event Free Survival for 
Development of Type 2 Diabetes Mellitus according to Dipstick 
Proteinuria. P value is derived by a log-rank test
Table 2 Risk of new-onset type 2 diabetes mellitus according to degree of proteinuria
Model 1: adjusted for sex, and age
Model 2: adjusted for sex, age, current smoking, physical activity, alcohol consumption, family history of diabetes, body mass index, and systolic blood pressure
Model 3: adjusted for sex, age, current smoking, physical activity, alcohol consumption, family history of diabetes, body mass index, systolic blood pressure, fasting 
glucose level, and estimated glomerular filtration rate
HR hazard ratio, CI indicates confidence interval
a New-onset type 2 diabetes mellitus
Degree of proteinuria Casea HR (95% CI)
Crude model Model 1 Model 2 Model 3
No proteinuria 21,086 1 (Ref ) 1 (Ref ) 1 (Ref ) 1 (Ref )
Trace proteinuria (±) 491 1.06 [0.97–1.16] 1.04 [0.95–1.14] 1.01 [0.92–1.10] 0.96 [0.88–1.05]
Overt proteinuria (≥ 1 +) 638 1.50 [1.38–1.62] 1.46 [1.35–1.58] 1.32 [1.22–1.42] 1.19 [1.10–1.29]
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chemotactic protein-1, endothelin-1, and nuclear factor-
kB [30, 31]. Secretion of these chemokines and inflam-
matory cytokines has been shown to induce insulin 
resistance, a major hallmark of T2DM pathogenesis 
[32–34]. That is to say, elevated levels of the inflamma-
tory biomarkers are predictors of the development of 
T2DM [35, 36]. The implications of systemic inflamma-
tion and proteinuria may explain the high risk of T2DM 
in patients with proteinuria.
Microvascular endothelial dysfunction is a typical clini-
cal feature found in patients with proteinuria [36, 37]. 
β-cells of the pancreatic islets secrete insulin and play a 
major role in glycemic control and the development of 
diabetes [38]. The pancreatic islet is highly vassalized 
with an extensive capillary network, which is essential 
for the survival and function of islet β-cells [39]. The 
islet endothelial dysfunction contributes to impaired 
β-cell function in diabetes [40]. Furthermore, impaired 
endothelial permeability disrupts insulin delivery to the 
skeletal muscle, liver, or adipose tissue, thereby limit-
ing insulin action [41]. Many epidemiological studies 
have reported that biomarkers of endothelial dysfunc-
tion could be predictors of T2DM development [9, 42]. 
Although it is uncertain whether endothelial dysfunction 
is a consequence or preceding factor of T2DM [12], the 
link between endothelial dysfunction and diabetes may 
explain the increased risk of T2DM in patients with pro-
teinuria, the result of current study.
The kidneys play a central role in glucose homeostasis, 
and impaired renal proximal tubules may be another con-
tributing factor in the development of T2DM in patients 
with proteinuria [43]. The kidneys filter approximately 
180 g of glucose per day, and glucose reabsorption in the 
kidney is primarily mediated by sodium glucose cotrans-
porters 1 and 2 in the proximal tubule, which help regu-
late blood glucose levels [44]. The proximal tubule is also 
a major site of albumin reabsorption in the kidneys [45]. 
Damaged proximal tubules, leading to the presence of 
proteinuria, may interfere with the reabsorption of glu-
cose and regulation of glucose homeostasis.
Due to the limitation of the observational design 
without interventions, we could not conclude whether 
proteinuria had a causal effect on the risk of T2DM 
(mediator) or that proteinuria only reflected an underly-
ing inflammatory or other deteriorating condition asso-
ciated with an increased risk of T2DM (risk marker). 
However, substantial clinical and experimental evidence 
has suggested that systemic inflammation and endothe-
lial dysfunction can contribute to the pathogenesis and 
development of T2DM, suggesting they are risk factors 
for diabetes [10, 46]. Therefore, we supposed that pro-
teinuria may be a potential treatment target for reduc-
ing the development of T2DM and improving glycemic 
control. The findings of the current study, namely, the 
dose–response increase in T2DM risk according to the 
degree of proteinuria and the concurrent change in the 
risk according to the change in proteinuria, suggest that 
proteinuria reduction would have a beneficial effect on 
the prevention of diabetes. Intense exercise, heat waves 
and extreme temperatures, and consumption of dietary 
protein in excess of recommended amounts accelerate a 
progressive loss of renal capacity leading to proteinuria 
[47–49]. However, we could not consider these variable 
due to unavailability of such information from the health-
insurance database. In addition, modifications in lifestyle 
factors, anti-proteinuric therapies and anti-hypertensive 
therapies such as angiotensin-converting enzyme inhibi-
tors or angiotensin receptor blockers have been reported 
to have an additive effect on the reduction of proteinuria 
[50–52]. Thus, further research is needed to evaluate the 
effect of these interventions on reducing proteinuria to 
aid in the prevention of T2DM.
We should acknowledge several limitations of cur-
rent study. First, current study had a retrospective 
Table 3 Risk of type 2 diabetes mellitus risk according to change in proteinuria status
Model 1: adjusted for sex and age
Model 2: adjusted for sex, age, current smoking, physical activity, alcohol consumption, family history of diabetes, body mass index, systolic blood pressure
Model 3: adjusted for sex, age, current smoking, physical activity, alcohol consumption, family history of diabetes, body mass index, systolic blood pressure, fasting 
glucose level, and estimated glomerular filtration rate
HR hazard ratio,  CI indicates confidence interval
a New-onset type 2 diabetes mellitus
Change in proteinuria Participants 
(number)
Casea HR (95% CI)
Crude model Model 1 Model 2 Model 3
Negative/Trace → Negative/Trace 231,223 21,249 1 (Ref ) 1 (Ref ) 1 (Ref ) 1 (Ref )
Negative/Trace →  ≥ 1 + 4380 569 1.46 [1.35–1.59] 1.44 [1.32–1.56] 1.30 [1.19–1.41] 1.18 [1.08–1.28]
 ≥ 1 +  → Negative/Trace 2660 276 1.15 [1.02–1.29] 1.19 [1.05–1.33] 1.12 [0.99–1.26] 1.13 [1.01–1.28]
 ≥ 1 +  →  ≥ 1 + 416 68 1.88 [1.48–2.39] 1.77 [1.40–2.25] 1.53 [1.20–1.94] 1.39 [1.10–1.76]
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observational design without interventions; it was there-
fore difficult to explain the exact mechanism between 
proteinuria and the risk for new-onset T2DM. Second, 
urine dipstick proteinuria was assessed by a single meas-
urement, which may have a measurement error. Third, 
as our study’s participants were limited to the Korean 
population, the results should be interpreted with cau-
tion. Nonetheless, this study was strengthened by its use 
of large-scale reliable data from the NHIS, representing 
nationwide health information on the Korean population, 
and its evaluation of the long-term risk for new-onset 
T2DM through both health claims data and serially per-
formed health screening examinations.
Conclusions
In conclusion, the present study found that dipstick pro-
teinuria was an independent risk factor for the develop-
ment of new-onset T2DM. The risk of T2DM increased 
proportionally with the severity of dipstick proteinuria. 
Further large-scale clinical and experimental studies 
should be conducted to investigate the exact mechanisms 
between of them and to determine whether proteinuria is 
a potential treatment target for the prevention and con-
trol of T2DM.
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